Search clinical trials for: AZD7442

Total 59 results

AstraZeneca

Completed

Phase I Double-blind, Placebo-controlled Study of AZD7442

COVID-19

Japan
AstraZeneca

Completed

A Study to Evaluate the Safety and Tolerability of AZD7442 in Healthy Chinese Adults

Healthy Volunteer | Coronavirus Disease 2019 (COVID-19)

China
AstraZeneca

Completed

A Study to Evaluate the Safety and Tolerability of AZD7442 in Chinese Adults

Coronavirus Disease 2019 (COVID-19)

China
AstraZeneca
Parexel

Completed

AZD7442 - a Potential Combination Therapy for the Prevention and Treatment of COVID-19

COVID-19

United Kingdom
Peking University
AstraZeneca

Recruiting

Phase 1 Trial of AZD6422 in CLDN18.2+ GI Tumors

Gastrointestinal Tumors

China
University of Rome Tor Vergata

Completed

EVALUATION OF DIFFERENT PROPHYLACTIC INTERVENTIONS TOWARD COVID-19 IN SOLID ORGAN TRANSPLANT PATIENTS

COVID-19 Pandemic | Transplant-Related Disorder

Italy
AstraZeneca
Quintiles, Inc.

Completed

This is a Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of AZD9742 After Single IV Doses in Healthy Subjects

Healthy

United States
AstraZeneca
Iqvia Pty Ltd

Active, not recruiting

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult. (PROVENT)

COVID-19

United States, Belgium, France, Spain, United Kingdom
AstraZeneca

Withdrawn

Study in Healthy Males to Assess Distribution, Metabolism, and Excretion of Radio-labelled AZD9742 Administered as a 2-hour Infusion

Healthy

United States
AstraZeneca

Completed

A Bioavailability Study Comparing Modified-release Capsules and Immediate Release Capsules in Fed and Fasting Conditions

Healthy

Sweden
AstraZeneca

Completed

AZD9742 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese Subjects

Healthy

United States
National Cancer Institute (NCI)

Completed

AZD7451 for Recurrent Gliomas

Glioblastoma Multiforme

United States
AstraZeneca

Completed

Study to Assess Safety, Tolerability and Pharmacokinetics After Single Doses of AZD1446 to Healthy Volunteers (SAD)

Healthy

Sweden
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD5462 Following Single and Multiple Ascending Dose Administration to Healthy Volunteers

Healthy Participants

United States
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Modified-Release Formulations of AZD1446 After Oral Single and Repeated Doses

Healthy

Japan
AstraZeneca

Completed

A Study in Healthy Volunteers to Assess Safety and Blood Levels of AZD9742 After Multiple Doses Over 14 Days

Healthy

United States
AstraZeneca

Completed

Study to Investigate Safety and Tolerability of a Single Dose of AZD6482

Antiplatelet Effect
AstraZeneca

Active, not recruiting

AZD7442 Pharmacokinetics, Pharmacodynamics, and Safety Evaluation in Pediatrics (TRUST)

SARS-CoV-2

United States, Belgium, United Kingdom, Brazil, Germany
AstraZeneca

Not yet recruiting

eVusheld Assessment reaL wORld Effectiveness in DoD Health System (VALOR DoD)

COVID-19; SARS-CoV-2; 2019 Novel Coronavirus Disease
AstraZeneca

Completed

4 Week, Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease (ROBIN)

Mild to Moderate Alzheimer's Disease

Czech Republic, Hungary, Slovakia
AstraZeneca

Completed

Study to Investigate Safety, Tolerability and Pharmacokinetics With Single and Multiple Ascending Doses of AZD1446

Healthy

Sweden
AstraZeneca

Completed

Study to Investigate the Efficacy and Tolerability of AZD1446 in Adult ADHD Patients.

Adult ADHD

United States
AstraZeneca
Parexel

Completed

A Bioavailability and Food Effect Study of AZD5462 in Healthy Volunteers

Healthy Participants

United States
AstraZeneca

Terminated

A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19 (ENDURE)

Coronavirus Disease 2019 (COVID-19)

United States
AstraZeneca

Completed

Study to Assess Safety, Tolerability and Pharmacokinetics After Single and Multiple Doses of AZD1446 to Japanese Subject

Healthy

Japan
MediMergent, LLC

Terminated

Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2

SARS-CoV-2 Infection

United States
AstraZeneca
Iqvia Pty Ltd

Completed

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults (STORM CHASER)

COVID-19

United States, United Kingdom
AstraZeneca

Completed

Assessing the Safety and Tolerability of a Single IV Dose of AZD9742 in Healthy Elderly Male and Female Subjects

Healthy | Elderly | Tolerability

United States
AstraZeneca

Completed

A Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD1446 Administered for 4 Weeks in Elderly Healthy Volunteers

Healthy

Sweden
AstraZeneca

Completed

A Study in Healthy Volunteers and Patients With Mild Asthma to Investigate the Safety, Anti-inflammatory Effect of Inhaled AZD0449

Asthma

New Zealand, United Kingdom
AstraZeneca

Completed

A Phase IIa Study to Investigate the Efficacy and Safety of AZD7624 in Chronic Obstructive Pulmonary Disease (COPD) Patients While on Maintenance Therapy

Chronic Obstructive Pulmonary Disease COPD

United States, Netherlands, Argentina, South Africa, Chile, Peru
AstraZeneca

Completed

Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults (TACKLE)

COVID-19

United States, Spain, United Kingdom, Brazil, Germany, Ukraine, Japan, Italy, Poland, Russian Federation, Mexico, Czechia, Argentina, Hungary, Peru
AstraZeneca

Not yet recruiting

A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure (LUMINARA)

Chronic Heart Failure
National Institute of Allergy and Infectious Diseases...
National Heart, Lung, and Blood Institute (NHLBI); AstraZeneca; University of... and other collaborators

Active, not recruiting

AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

COVID-19

United States, Denmark, Greece, Poland, Singapore, Spain, Switzerland, Uganda, United Kingdom
AstraZeneca

Completed

Study to Assess Effect of Device and Formulation on Pharmacokinetics (PK) of AZD1402

Asthma

United Kingdom
AstraZeneca

Completed

Positron Emission Tomography (PET) Study

Healthy

Sweden
AstraZeneca

Active, not recruiting

Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study (SUPERNOVA)

COVID-19, SARS-CoV-2

United States, Belgium, Canada, France, Spain, Denmark, Thailand, Vietnam, Korea, Republic of, United Kingdom, Malaysia, Israel, Taiwan, Australia, Germany, Poland, Singapore, United Arab Emirates
AstraZeneca
Parexel

Terminated

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Elarekibep in Healthy Japanese Subjects

Healthy Subjects (Indication: Asthma)

United Kingdom
National Institute of Allergy and Infectious Diseases...
Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; AIDS Clinical Trials... and other collaborators

Completed

ACTIV-2: A Study for Outpatients With COVID-19

Covid19 | Coronavirus

United States, Argentina, Brazil, Guatemala, Mexico, Philippines, Puerto Rico, South Africa, Canada
AstraZeneca

Completed

Study to Evaluate Pharmacokinetic Comparability Between AZD7442 Co-formulation (AZD8895 + AZD1061) vs AZD8895 and AZD1061 Individually in Adult Healthy Participants

Corona Virus Disease

United States
AstraZeneca

Completed

A First Time in Man Study to Asses the Safety and Tolerability of AZD7624 in Healthy Subjects

Chronic Obstructive Pulmonary Disease (COPD)

United Kingdom
Cancer Research UK

Terminated

A Phase I Study of AZD0424 Alone and in Combination in Advanced Solid Tumours (AZD0424)

Advanced Solid Tumours

United Kingdom
The Netherlands Cancer Institute
Leiden University Medical Center; University Medical Center Nijmegen

Recruiting

Sarcomas and DDR-Inhibition; a Combined Modality Study (SADDRIN-1)

Soft Tissue Sarcoma Adult

Netherlands
AstraZeneca

Completed

To Assess the Safety, Tolerability, and Pharmacokinetics of AZD7624 in Healthy Volunteers and COPD Patients

Healthy Subjects | COPD

United Kingdom
AstraZeneca

Completed

Study to Investigate the Effect of a Single Dose of AZD7624 on Inflammation Caused by an Endotoxin Challenge

LPS Challenge, Neutrophils

United Kingdom
AstraZeneca
Parexel

Completed

A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.

Advanced Malignancies

United Kingdom, United States
AstraZeneca

Terminated

To Evaluate Effects of AZD1446, Placebo and Donepezil in Patients With Alzheimer's Disease

Alzheimer´s Disease

Russian Federation, Ukraine
AstraZeneca

Terminated

Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan

Cancer | Advanced Solid Tumors | Advanced Solid Malignancies

United States
National Institute of Allergy and Infectious Diseases...
Eli Lilly and Company; National Heart, Lung, and Blood Institute (NHLBI); Gla... and other collaborators

Completed

ACTIV-3: Therapeutics for Inpatients With COVID-19 (TICO)

Covid19

United States, Denmark, Greece, Nigeria, Poland, Singapore, Spain, Switzerland, Uganda, United Kingdom
Boehringer Ingelheim

Completed

Effectiveness of Triple Therapy in COPD

Pulmonary Disease, Chronic Obstructive

United Kingdom

3

Subscribe